Kuros returns to profit in H1 FY26 with net profit USD 4.4 million; revenue rises 45% to USD 92.4 million

(AWP Alliance News) - Kuros Biosciences posted H1 2026 product sales growth of 45% to USD 92.4 million, while IFRS net profit turned positive at USD 4.4 million, compared with a net loss a year earlier. IFRS EBITDA rose 46% to USD 7.4 million, while IFRS operating profit increased to USD 5.18 million.

Adjusted EBITDA climbed 61% to USD 12.5 million, lifting the adjusted EBITDA margin by 1.3 percentage points to 13.6%. Cash and cash equivalents fell to USD 9.7 million as of June 30 from USD 19.8 million at year-end, following investments in U.S. and Netherlands manufacturing, R&D innovation, and working capital, while the group reaffirmed 2026 guidance for at least 35% sales growth and an adjusted EBITDA margin of around 14%.

http://www.globenewswire.com/newsroom/news.html?d=1001257359

Disclaimer: This news brief was created using generative artificial intelligence. Kuros Biosciences AG published the original content used to generate this news brief via GlobeNewswire on August 13, 2026, and is solely responsible for the information contained therein.